Effect of the HR2 Haplotype on the Relative Risk of Thrombosis (RR) in Patients With Factor V R506Q or a Double Thrombophilic Defect
| . | Factor V R506Q . | Double Defect . | ||
|---|---|---|---|---|
| HR2− . | HR2+ . | HR2− . | HR2+ . | |
| No. of subjects | 238 | 23 | 39 | 2 |
| Sex (M/F) | 99/139 | 10/13 | 18/21 | 1/1 |
| Median age at first event (range) | 52 (20-80) | 46 (15-57) | 25 (15-50) | 19 (—) |
| No. with VT | 18 | 4 | 7 | 1 |
| Patient-years | 9909 | 861 | 1560 | 56 |
| Incidence of VT (%/yr) | 0.18 | 0.47 | 0.45 | 1.8 |
| RR (95% CI) | 4.2 (1.6-11.3) | 10.9 (2.9-40.6) | 10.5 (3.3-33.1) | 41.9 (4.9-359) |
| . | Factor V R506Q . | Double Defect . | ||
|---|---|---|---|---|
| HR2− . | HR2+ . | HR2− . | HR2+ . | |
| No. of subjects | 238 | 23 | 39 | 2 |
| Sex (M/F) | 99/139 | 10/13 | 18/21 | 1/1 |
| Median age at first event (range) | 52 (20-80) | 46 (15-57) | 25 (15-50) | 19 (—) |
| No. with VT | 18 | 4 | 7 | 1 |
| Patient-years | 9909 | 861 | 1560 | 56 |
| Incidence of VT (%/yr) | 0.18 | 0.47 | 0.45 | 1.8 |
| RR (95% CI) | 4.2 (1.6-11.3) | 10.9 (2.9-40.6) | 10.5 (3.3-33.1) | 41.9 (4.9-359) |
The reference group is that of individuals with no inherited defects and no HR2 haplotype (n = 300; I = 0.043%/year; RR = 1.0).
Abbreviations: HR2+, positive for HR2 haplotype; HR2−, negative for HR2 haplotype.